joint with Molecular Biology of the Vasculature
Organizer(s): Peter Libby and Shaun R. CoughlinDate: April 02 - 07, 2006
Location: Keystone Resort, Keystone, CO, USA
The field of atherothrombosis is poised for advances in basic science and novel therapeutics, yet faces considerable challenges to clinical translation due to 1) the very success of current therapies (rendering event rates low and hence clinical trials large and lengthy) and 2) the lack of validated predictors of clinical outcomes to evaluate new therapies short of endpoint trials and to target cost-effective preventive therapies to asymptomatic individuals nonetheless at high risk, as well as to those with established disease. Bringing basic science discoveries to the bedside with minimum delay will require major advances. This meeting will bring together investigators of various disciplines to confront these issues. Emerging science of genetics, lipid metabolism, metabolic syndrome, stem cell biology, thrombosis will be coupled with discussions of emerging biomarkers and rapidly evolving imaging technologies. This conjunction should spur progress in confronting these challenges and reducing the rapidly advancing ravages of atherothrombosis worldwide.
Scholarship Deadline: December 1 2005
Discounted Abstract Deadline: December 1 2005
Abstract Deadline: December 28 2005
Discounted Registration Deadline: February 2 2006
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Educational grant from Lilly USA, LLC
Esperion Therapeutics, a Division of Pfizer Global Research & Development
Portola Pharmaceuticals Inc.
Schering-Plough Research Institute